Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Income (2016 - 2025)

Historic Net Income for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Net Income rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • Latest data reveals that Heron Therapeutics reported Net Income of -$4.1 million as of Q3 2025, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Net Income registered a high of $4.2 million during Q4 2024, and its lowest value of -$62.9 million during Q1 2022.
  • Moreover, its 5-year median value for Net Income was -$24.9 million (2023), whereas its average is -$27.2 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 2074.11% in 2022, then soared by 16573.57% in 2025.
  • Quarter analysis of 5 years shows Heron Therapeutics' Net Income stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then tumbled by 198.08% to -$4.1 million in 2025.
  • Its Net Income stands at -$4.1 million for Q3 2025, versus -$1.6 million for Q2 2025 and $3.2 million for Q1 2025.